Skip to main content
Inflammatory Bowel Diseases logoLink to Inflammatory Bowel Diseases
. 2021 Oct 6;28(3):494. doi: 10.1093/ibd/izab224

Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

Stefanie Howaldt 1,, Eugeni Domènech 2, Nicholas Martinez 3, Carsten Schmidt 4, Bernd Bokemeyer 5, on behalf of the AEGIS Trialists
PMCID: PMC8889305  PMID: 34612489

In the article titled “Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial”, the legends for Figures 3 and 4 were incorrect.

The incorrect legends read as follows:

“Figure 3. Mean change in Hb over 52 weeks of treatment with oral ferric maltol or IV ferric carboxymaltose (ITT population, observed patients). P values shown for test of null hypothesis of inferiority in risk difference with noninferiority margin of 20%.”.

“Figure 4. Patients achieving ≥1 and ≥2 g/dL increases, and normalization of Hb concentration between baseline and week 12 (ITT population with multiple imputation). P values shown for test of null hypothesis of inferiority in risk difference with noninferiority margin of 20%.”.

The legends should read as follows:

“Figure 3. Mean change in Hb over 52 weeks of treatment with oral ferric maltol or IV ferric carboxymaltose (ITT population). P values shown for least-squares mean change from baseline, difference between groups.”.

“Figure 4. Patients achieving ≥1 and ≥2 g/dL increases, and normalization of Hb concentration between baseline and week 12 (ITT population with multiple imputation). P values shown for risk difference between groups.”.

These errors have been corrected online and in print.


Articles from Inflammatory Bowel Diseases are provided here courtesy of Oxford University Press

RESOURCES